You are on the dollar here, I now share the same concerns - revenus might better this year (sure as hell hope so), but I don't see the SP going north of 30 cents unless that cash balance buffs up - the capital market environment is very risk averse at this stage, better avenues for institutions to park funds.
Also Osteopore easily needs another capital raise if not 2 more - revenue growth will be accompanied by milestone payments which eat into top line GP. Their internal liquidity cannot be significant unless they see annual revenues go above that 5 - 6 million mark. Without that self sustainability the SP isn't going in our favour anytime soon, expect a few years as period of wait time.
**based on current public information
OSX Price at posting:
7.7¢ Sentiment: Buy Disclosure: Held
